Page last updated: 2024-12-06
propinox
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
propinox: used as premedication when performing endoscopic retrograde cholangiopancreatography (ERCP) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 17700 |
| CHEMBL ID | 1872101 |
| CHEBI ID | 135433 |
| SCHEMBL ID | 2111437 |
| MeSH ID | M0231218 |
Synonyms (35)
| Synonym |
|---|
| pargeverinum [inn-latin] |
| pargeverina [inn-spanish] |
| be 50 |
| 2-(dimethylamino)ethyl diphenyl(2-propynyloxy)acetate |
| pargeverine |
| benzeneacetic acid, alpha-phenyl-alpha-(2-propynyloxy)-, 2-(dimethylamino)ethyl ester |
| propinox |
| brn 2226014 |
| terisal |
| diphenyl(2-propynyloxy)acetic acid 2-(dimethylamino)ethyl ester |
| pargeverine [inn] |
| acetic acid, diphenyl(2-propynyloxy)-, 2-(dimethylamino)ethyl ester |
| NCGC00164558-01 |
| CHEBI:135433 |
| viadil (tn) |
| 13479-13-5 |
| pargeverine (inn) |
| D07466 |
| pargeverinum |
| unii-uc61hm8fx0 |
| pargeverina |
| uc61hm8fx0 , |
| pargeverine hcl |
| pargeverine [who-dd] |
| pargeverin |
| CHEMBL1872101 |
| viadil |
| benzeneacetic acid, .alpha.-phenyl-.alpha.-(2-propynyloxy)-, 2-(dimethylamino)ethyl ester |
| QNPHCSSJLHAKSA-UHFFFAOYSA-N |
| DTXSID1048386 |
| SCHEMBL2111437 |
| pargevarine hcl |
| 2-(dimethylamino)ethyl 2,2-diphenyl-2-prop-2-ynoxyacetate |
| Q27291011 |
| n,n-dimethyl-[2-(2,2-diphenyl)-2-prop-2-ynyloxyacetoxy]ethylamine |
Research Excerpts
Overview
Propinox is an antispasmodic drug frequently used in the treatment of disorders of the gastrointestinal tract, the uterus and the gallbladders. Little is known about its relaxing activity in gallbladder tissue.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Propinox is an antispasmodic drug frequently used in the treatment of disorders of the gastrointestinal tract, the uterus and the gallbladder, but little is known about its relaxing activity in gallbladder tissue. " | ( Antispasmodic action of propinox on the isolated human gallbladder: possible mechanism of action. Baistrocchi, RL; de los Santos, AR; Di Girolamo, G; Marti, ML; Orti, E; Pico, JC, 1999) | 2.05 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| ", and establish a dose-response relation according to three dose levels (10, 20 and 30 mg), vs." | ( Propinox in biliary colic: a multicenter, randomized, prospective and parallel double-blind study of three doses of propinox versus placebo in acute biliary colic pain. de los Santos, AR; Del Prete, C; Di Girolamo, G; Diego Espinosa, J; Martí, ML; Morano, MA; Tobar, JC, 1999) | 1.75 |
| " and to establish a dose-response relationship according to three dose levels (10 mg, 20 mg and 30 mg), vs." | ( Propinox in intestinal colic: multicenter randomized prospective double-blind study of three doses of propinox vs. placebo in acute intestinal colic pain. de los Santos, AR; Di Girolamo, G; Fandiño, D; Godoy, MI; Greggio, A; Martí, ML; Morano, MA; Palomino, G; Valdés Quintana, E, 2000) | 1.75 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| diarylmethane | Any compound containing two aryl groups connected by a single C atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 62.64
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (62.64) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (57.14%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (42.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||